Halozyme Therapeutics Inc. Common Stock vs News Corporation Class A Common Stock — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.3 (market cap $12.58B), while News Corporation Class A Common Stock trades at $29.06 (market cap $16.14B). The key difference: News Corporation Class A Common Stock is the larger of the two by market cap, and News Corporation Class A Common Stock pays a 0.69% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and News Corporation Class A Common Stock for 0 Days on average.
| HALO | NWSA | |
|---|---|---|
Market Cap | $12.58B | $16.14B |
Volume | 2,179,278 | 4,310,610 |
Sector | Health | Media |
52-Week High | $115.22 | $31.19 |
52-Week Low | $61.63 | $22.40 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $14.49B | $16.96B |
Dividend Yield | — | 0.69% |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →News Corporation operates businesses in news and information services, digital real estate, and book publishing. Its brands include Dow Jones, The Wall Street Journal, HarperCollins, Realtor.com, and realestate.com.au.
Read more on NWSA →